As a patient foundation you have already done the work to bring patients together. Now is your chance to get their voices heard by pharmaceutical companies.
Announcing the Launch of our new subscription based education
The Atlas
Visit https://t.co/FMJMxMCpuf to register for our kick-off meeting on Thursday, September 28, 2023.
Announcing the Launch of our new subscription based education
The Atlas
Visit https://t.co/FMJMxMCpuf to register for our kick-off meeting on Thursday, September 28, 2023.
We're so excited to share our new episode with you. Susan Geoghegan is an amazing mom of two rare babies given the challenge in life of Mitochondrial Disease effecting the FBXL4 gene.
https://t.co/PpkEwEy7kP
After some rapid fire recording we have a handful of episodes in the works! Follow us wherever you listen to podcasts to be notified when a new episode is available. (It should be every other Thursday going forward, but being a rare parent can get unpredictable.) #RareDisease
We're always looking for new guests, if you're the parent of a child with a rare disease and would like to tell your family's story send us a DM. #RareDisease#rareis
Curious about how the 21st Century Cures Act will impact your organization?
You'll enjoy our interview with Micky Tripathi, National Coordinator for Health IT at HHS.
Watch the interview here: https://t.co/cCAvzYVhnI
@ONC_HealthIT#HITSM
It's been awhile since we've been on the road, what conferences should @SalemOaks hit this year? Any smaller ones that we might not have heard of? #hcldr
Twice now I’ve heard #patientengagement referred to as “fluffy stuff” 😡 The time ⏰ and money 💰 we will save from solutions that are co-designed with and led by #patients which reduce study delays and increase retention will not be “fluffy”, I guarantee it 💪 #clinicalresearch
When patient advocacy groups partner with drug makers, awesome things can happen. Patient groups will always be closer to community members and with it a symbiotic relationship can develop. This is the kind of thing leadership development programs need to teach inside pharma.
Today on @BeLEMSaware Podcast: Jill Pollander, VP of Patient Services at @RareDiseases, shares how you can participate in #RDD2023. Join millions who are elevating awareness for the #raredisease community today. Listen now: https://t.co/dLfWVNCJ6n #RareDiseaseDay2023
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
Click here to read the full press release: https://t.co/hVpJ0ZUMhO